menu search

CASBF / China's CanSinoBIO H1 revenue drops on weaker COVID shot demand

China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots. Read More
Posted: Aug 28 2022, 21:05
Author Name: Reuters
Views: 102571

CASBF News  

Riding Covid Vaccine Highs, CanSino Plans Swiss Listing

By Seeking Alpha
January 17, 2023

Riding Covid Vaccine Highs, CanSino Plans Swiss Listing

After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland. Sales could more_horizontal

China 'Definitely' Needs 2nd Covid Booster Dose: CanSino Biologics CEO

By Bloomberg Markets and Finance
December 6, 2022

China 'Definitely' Needs 2nd Covid Booster Dose: CanSino Biologics CEO

Yu Xuefeng, chief executive officer of CanSino Biologics Inc., a Tianjin, China-based drugmaker that's rolling out a vaccine that can be inhaled, di more_horizontal

China's CanSinoBIO H1 revenue drops on weaker COVID shot demand

By Reuters
August 28, 2022

China's CanSinoBIO H1 revenue drops on weaker COVID shot demand

China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine ma more_horizontal


Search within

Pages Search Results: